{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:42:57Z","timestamp":1787769777812,"version":"build-2784847793"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Klin Intensivmed Notfmed"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s00063-023-01034-7","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T22:01:30Z","timestamp":1686952890000},"page":"464-469","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Harnwegsinfektionen einschlie\u00dflich Pyelonephritis","Urinary tract infections including pyelonephritis"],"prefix":"10.1007","volume":"118","author":[{"given":"Florian M. E.","family":"Wagenlehner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,16]]},"reference":[{"issue":"10","key":"1034_CR1","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41585-020-0362-4","volume":"17","author":"FME Wagenlehner","year":"2020","unstructured":"Wagenlehner\u00a0FME, Bjerklund Johansen\u00a0TE, Cai\u00a0T, Koves\u00a0B, Kranz\u00a0J, Pilatz\u00a0A et\u00a0al (2020) Epidemiology, definition and treatment of complicated urinary tract infections. Nat Rev Urol 17(10):586\u2013600","journal-title":"Nat Rev Urol"},{"issue":"4","key":"1034_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.euf.2016.08.006","volume":"2","author":"Z Tandogdu","year":"2016","unstructured":"Tandogdu\u00a0Z, Cai\u00a0T, Koves\u00a0B, Wagenlehner\u00a0F, Bjerklund-Johansen\u00a0TE (2016) Urinary tract infections in immunocompromised patients with diabetes, chronic kidney disease, and kidney transplant. Eur Urol Focus 2(4):394\u2013399","journal-title":"Eur Urol Focus"},{"key":"1034_CR3","unstructured":"Infektionen NRfSvn. Deutsche nationale Punkt-Pr\u00e4valenzerhebung zu nosokomialen Infektionen und Antibiotika-Anwendung. 2016 23. Apr. 2023."},{"issue":"10219","key":"1034_CR4","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S0140-6736(19)32989-7","volume":"395","author":"KE Rudd","year":"2020","unstructured":"Rudd\u00a0KE, Johnson\u00a0SC, Agesa\u00a0KM, Shackelford\u00a0KA, Tsoi\u00a0D, Kievlan\u00a0DR et\u00a0al (2020) Global, regional, and national sepsis incidence and mortality, 1990\u20132017: analysis for the Global Burden of Disease Study. Lancet 395(10219):200\u2013211","journal-title":"Lancet"},{"key":"1034_CR5","unstructured":"(CDER) USDoHaHSFaDACfDEaR. Complicated Urinary Tract Infections: Developing Drugs for Treatment Guidance for Industry. 2018."},{"key":"1034_CR6","unstructured":"(CHMP). EMAECfHMP. Guideline on the evaluation of medicinal products indicated for treatment of bacterial infections, Rev. 3. (EMA\/844951\/2018 Rev. 3). In: (EMA) EMA, editor. 2018. p.\u00a01\u201330."},{"key":"1034_CR7","doi-asserted-by":"publisher","unstructured":"Kadry N, Natarajan M, Bein E, Kim P, Farley J (2023) Discordant clinical and microbiological outcomes are associated with late clinical relapse in clinical trials for complicated urinary tract infections (cUTI). Clini Infect Dis 2023 76(10):1768\u20131775. https:\/\/doi.org\/10.1093\/cid\/ciad010","DOI":"10.1093\/cid\/ciad010"},{"issue":"3","key":"1034_CR8","doi-asserted-by":"publisher","first-page":"e1157","DOI":"10.1093\/cid\/ciac692","volume":"76","author":"J Howard-Anderson","year":"2023","unstructured":"Howard-Anderson\u00a0J, Hamasaki\u00a0T, Dai\u00a0W, Collyar\u00a0D, Rubin\u00a0D, Nambiar\u00a0S et al (2023) Improving traditional registrational trial end points: development and application of a\u00a0desirability of outcome ranking end point for complicated urinary tract infection clinical trials. Clin Infect Dis 76(3):e1157\u2013e1165","journal-title":"Clin Infect Dis"},{"key":"1034_CR9","first-page":"979","volume-title":"Urogenital Infections","author":"TEBH Bjerklund Johansen","year":"2010","unstructured":"Bjerklund Johansen\u00a0TEBH, Cek\u00a0M, Grabe\u00a0M, Tenke\u00a0P, Wagenlehner\u00a0FME, Naber\u00a0KG (2010) Critical review of current definitions of urinary tract infections and proposal of an EAU\/ESIU classification system. In: Naber\u00a0KGSA, Heyns\u00a0CF, Matsumoto\u00a0T, Shoskes\u00a0DA, Bjerklund Johansen\u00a0TE (Hrsg) Urogenital Infections. International Consultation on Urological Diseases (ICUD) and European Association of Urology, Arnheim, S\u00a0979\u2013993"},{"issue":"Suppl","key":"1034_CR10","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ijantimicag.2011.09.009","volume":"38","author":"TE Johansen","year":"2011","unstructured":"Johansen\u00a0TE, Botto\u00a0H, Cek\u00a0M, Grabe\u00a0M, Tenke\u00a0P, Wagenlehner\u00a0FM et\u00a0al (2011) Critical review of current definitions of urinary tract infections and proposal of an EAU\/ESIU classification system. Int J Antimicrob Agents 38(Suppl):64\u201370","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"1034_CR11","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1186\/s12879-021-06435-7","volume":"21","author":"GK Bunduki","year":"2021","unstructured":"Bunduki\u00a0GK, Heinz\u00a0E, Phiri\u00a0VS, Noah\u00a0P, Feasey\u00a0N, Musaya\u00a0J (2021) Virulence factors and antimicrobial resistance of uropathogenic Escherichia coli (UPEC) isolated from urinary tract infections: a\u00a0systematic review and meta-analysis. BMC Infect Dis 21(1):753","journal-title":"BMC Infect Dis"},{"key":"1034_CR12","first-page":"1","volume-title":"Mikrobiologisch-infektiologische Qualit\u00e4tsstandards (MiQ)","author":"S Schubert","year":"2020","unstructured":"Schubert\u00a0S, Podschun\u00a0R, Gatermann\u00a0S, F\u00fcnfst\u00fcck\u00a0R, Naber\u00a0KG, Schimanski\u00a0S, Wagenlehner\u00a0F (2020) Harnwegsinfektionen. In: Abele-Horn\u00a0M, Becker\u00a0K, Herrmann\u00a0M, Kniehl\u00a0E, Mauch\u00a0H, Podbielski\u00a0A, R\u00fcssmann\u00a0H, Schubert\u00a0S, Zimmermann\u00a0S (Hrsg) Mikrobiologisch-infektiologische Qualit\u00e4tsstandards (MiQ), 2.\u00a0Aufl. Elsevier, M\u00fcnchen, S 1\u201382","edition":"2"},{"issue":"4","key":"1034_CR13","doi-asserted-by":"publisher","first-page":"e0214710","DOI":"10.1371\/journal.pone.0214710","volume":"14","author":"Z Tandogdu","year":"2019","unstructured":"Tandogdu\u00a0Z, Kakariadis\u00a0ETA, Naber\u00a0K, Wagenlehner\u00a0F, Bjerklund Johansen\u00a0TE (2019) Appropriate empiric antibiotic choices in health care associated urinary tract infections in urology departments in Europe from 2006 to 2015: A Bayesian analytical approach applied in a\u00a0surveillance study. PLoS ONE 14(4):e214710","journal-title":"PLoS ONE"},{"issue":"10325","key":"1034_CR14","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","volume":"399","author":"Antimicrobial Resistance Collaborators","year":"2022","unstructured":"Antimicrobial Resistance Collaborators (2022) Global burden of bacterial antimicrobial resistance in 2019: a\u00a0systematic analysis. Lancet 399(10325):629\u2013655","journal-title":"Lancet"},{"issue":"9981","key":"1034_CR15","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","volume":"385","author":"FM Wagenlehner","year":"2015","unstructured":"Wagenlehner\u00a0FM, Umeh\u00a0O, Steenbergen\u00a0J, Yuan\u00a0G, Darouiche\u00a0RO (2015) Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a\u00a0randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet 385(9981):1949\u20131956","journal-title":"Lancet"},{"issue":"6","key":"1034_CR16","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1093\/cid\/ciw378","volume":"63","author":"FM Wagenlehner","year":"2016","unstructured":"Wagenlehner\u00a0FM, Sobel\u00a0JD, Newell\u00a0P, Armstrong\u00a0J, Huang\u00a0X, Stone\u00a0GG et al (2016) Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a\u00a0phase\u00a03 randomized trial program. Clin Infect Dis 63(6):754\u2013762","journal-title":"Clin Infect Dis"},{"issue":"13","key":"1034_CR17","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1001\/jama.2022.17034","volume":"328","author":"KS Kaye","year":"2022","unstructured":"Kaye\u00a0KS, Belley\u00a0A, Barth\u00a0P, Lahlou\u00a0O, Knechtle\u00a0P, Motta\u00a0P et\u00a0al (2022) Effect of cefepime\/enmetazobactam vs piperacillin\/tazobactam on clinical cure and microbiological eradication in patients with complicated urinary tract infection or acute Pyelonephritis: a randomized clinical trial. JAMA 328(13):1304\u20131314","journal-title":"JAMA"},{"key":"1034_CR18","doi-asserted-by":"publisher","unstructured":"Hamrick JC, Docquier JD, Uehara T, Myers CL, Six DA, Chatwin CL et al (2020) VNRX-5133 (Taniborbactam), a\u00a0broad-spectrum inhibitor of serine- and metallo-beta-lactamases, restores activity of cefepime in enterobacterales and Pseudomonas aeruginosa. Antimicrob Agents Chemother 64(3):e01963-19. https:\/\/doi.org\/10.1128\/AAC.01963-19","DOI":"10.1128\/AAC.01963-19"},{"issue":"6","key":"1034_CR19","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1021\/acs.jmedchem.9b01518","volume":"63","author":"B Liu","year":"2020","unstructured":"Liu\u00a0B, Trout\u00a0REL, Chu\u00a0GH, McGarry\u00a0D, Jackson\u00a0RW, Hamrick\u00a0JC et al (2020) Discovery of taniborbactam (VNRX-5133): a broad-spectrum serine- and metallo-beta-lactamase inhibitor for carbapenem-resistant bacterial infections. J\u00a0Med Chem 63(6):2789\u20132801","journal-title":"J Med Chem"},{"issue":"12","key":"1034_CR20","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/S1473-3099(18)30554-1","volume":"18","author":"S Portsmouth","year":"2018","unstructured":"Portsmouth\u00a0S, van Veenhuyzen\u00a0D, Echols\u00a0R, Machida\u00a0M, Ferreira\u00a0JCA, Ariyasu\u00a0M et al (2018) Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a\u00a0phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect Dis 18(12):1319\u20131328","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"1034_CR21","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S1473-3099(18)30722-9","volume":"19","author":"FME Wagenlehner","year":"2019","unstructured":"Wagenlehner\u00a0FME, Naber\u00a0KG (2019) Cefiderocol for treatment of complicated urinary tract infections. Lancet Infect Dis 19(1):22\u201323","journal-title":"Lancet Infect Dis"},{"issue":"14","key":"1034_CR22","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1056\/NEJMoa2105462","volume":"386","author":"PB Eckburg","year":"2022","unstructured":"Eckburg\u00a0PB, Muir\u00a0L, Critchley\u00a0IA, Walpole\u00a0S, Kwak\u00a0H, Phelan\u00a0AM et\u00a0al (2022) Oral tebipenem pivoxil hydrobromide in complicated urinary tract infection. N\u00a0Engl J Med 386(14):1327\u20131338","journal-title":"N Engl J Med"},{"issue":"9","key":"1034_CR23","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1093\/jac\/dkx139","volume":"72","author":"M Sims","year":"2017","unstructured":"Sims\u00a0M, Mariyanovski\u00a0V, McLeroth\u00a0P, Akers\u00a0W, Lee\u00a0YC, Brown\u00a0ML et al (2017) Prospective, randomized, double-blind, phase\u00a02 dose-ranging study comparing efficacy and safety of imipenem\/cilastatin plus relebactam with imipenem\/cilastatin alone in patients with complicated urinary tract infections. J\u00a0Antimicrob Chemother 72(9):2616\u20132626","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"1034_CR24","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1001\/jama.2018.0438","volume":"319","author":"KS Kaye","year":"2018","unstructured":"Kaye\u00a0KS, Bhowmick\u00a0T, Metallidis\u00a0S, Bleasdale\u00a0SC, Sagan\u00a0OS, Stus\u00a0V et al (2018) Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial. JAMA 319(8):788\u2013799","journal-title":"JAMA"},{"issue":"8","key":"1034_CR25","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jiac.2017.05.005","volume":"23","author":"C Malaisri","year":"2017","unstructured":"Malaisri\u00a0C, Phuphuakrat\u00a0A, Wibulpolprasert\u00a0A, Santanirand\u00a0P, Kiertiburanakul\u00a0S (2017) A randomized controlled trial of sitafloxacin vs. ertapenem as a\u00a0switch therapy after treatment for acute pyelonephritis caused by extended-spectrum beta-lactamase-producing Escherichia coli: A pilot study. J\u00a0Infect Chemother 23(8):556\u2013562","journal-title":"J Infect Chemother"},{"issue":"8","key":"1034_CR26","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1056\/NEJMoa1801467","volume":"380","author":"FME Wagenlehner","year":"2019","unstructured":"Wagenlehner\u00a0FME, Cloutier\u00a0DJ, Komirenko\u00a0AS, Cebrik\u00a0DS, Krause\u00a0KM, Keepers\u00a0TR et al (2019) Once-daily plazomicin for complicated urinary tract infections. N\u00a0Engl J Med 380(8):729\u2013740","journal-title":"N Engl J Med"}],"container-title":["Medizinische Klinik - Intensivmedizin und Notfallmedizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00063-023-01034-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00063-023-01034-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00063-023-01034-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T15:17:40Z","timestamp":1694704660000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00063-023-01034-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,16]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["1034"],"URL":"https:\/\/doi.org\/10.1007\/s00063-023-01034-7","relation":{},"ISSN":["2193-6218","2193-6226"],"issn-type":[{"value":"2193-6218","type":"print"},{"value":"2193-6226","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,16]]},"assertion":[{"value":"24 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F.M.E.\u00a0Wagenlehner deklariert pers\u00f6nliche Geb\u00fchren und andere von Achaogen, pers\u00f6nliche Geb\u00fchren von AstraZeneca, pers\u00f6nliche Geb\u00fchren und andere von Bionorica, andere von Enteris BioPharma, andere von Helperby Therapeutics, pers\u00f6nliche Geb\u00fchren von Janssen, pers\u00f6nliche Geb\u00fchren von MerLion, pers\u00f6nliche Geb\u00fchren von MSD, pers\u00f6nliche Geb\u00fchren und andere von OM Pharma\/Vifor Pharma, pers\u00f6nliche Geb\u00fchren von Pfizer, pers\u00f6nliche Geb\u00fchren von RosenPharma, pers\u00f6nliche Geb\u00fchren und andere von Shionogi, pers\u00f6nliche Geb\u00fchren von Venatorx, pers\u00f6nliche Geb\u00fchren von GSK, andere vom Deutschen Zentrum f\u00fcr Infektionsforschung (DZIF) (Standort Giessen-Marburg-Langen), andere von der Deutschen Forschungsgesellschaft (DFG).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}